Moderna Starts a Phase 2 Clinical Trial for Its COVID-19 Vaccine
Moderna (NASDAQ: MRNA) has enrolled the first participants in a phase 2 clinical trial testing mRNA-1273, its vaccine against the novel coronavirus that causes COVID-19.
The move puts the biotech one step closer to potentially having the first COVID-19 vaccine available in the U.S., although the timing isn't all that surprising. Moderna announced plans to start the mid-stage study in April, followed by an endorsement by the Food and Drug Administration last month. And phase 1 data for the vaccine released May 18 certainly looked promising enough to justify moving to mid-stage testing.
Image source: Getty Images.
Source Fool.com
